MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

New York, New York--(Newsfile Corp. - November 10, 2025) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MoonLake securities between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/MLTX.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) MoonLake misrepresented the efficacy of its drug candidate, sonelokimab (SLK), by claiming it was superior to other monoclonal antibodies despite lacking evidence of any proven advantages; (2) the Company repeatedly promoted SLK's superiority while knowingly omitting material facts about its comparative performance; (3) the Phase 3 trial results of SLK, which analysts described as "disastrous," revealed the drug's shortcomings and caused MoonLake's stock to lose nearly 90% of its value; and (4) as a result, the Company's public statements regarding SLK and its prospects were materially false and misleading throughout the Class Period. When the market learned the truth about MoonLake's misrepresentations, investors suffered significant damages.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/MLTX, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in MoonLake you have until December 15, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [e-mail]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270721

The MoonLake Immunotherapeutics Registered (A) Stock at the time of publication of the news with a raise of +1,22 % to 10,76USD on Nasdaq stock exchange (10. November 2025, 17:46 Uhr).